SavedAdd your journal

Journals / ANKEM Dergisi / 2026 / Cilt: 34 Sayı: 2

Pneumocystis jirovecii Positivity and Empirical Treatment Approach in Bronchoalveolar Lavage Samples

Bronkoalveolar Lavaj Örneklerinde Pneumocystis jirovecii Pozitifliği ve Ampirik Tedavi Yaklaşımı

Buket Erturk Sengel(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2182-4693
Özlem Alhan(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-2540-7945
Rabia Can Sarinoğlu(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7597-8279
Elif Tükenmez Tigen(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2027-4116
Zekaver Odabaşı(MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-8091-6999
Pages
57–64
Publication Date
2020-08-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In HIV-negative immunosuppressed patients, PJP should be considered, and treatment can be continued if no other factor could be shown and there is high suspicion after taking the required specimen and starting empirical treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pneumocystis jirovecii (PJ) is an opportunistic yeast-like fungus that causes pneumonia in immunosuppressed patients.
📊
Key Findings & Data:In this study, PJ polymerase chain reaction (PCR) positivity rate, patient risk factors, clinical and laboratory findings were evaluated retrospectively in patients with suspected Pneumocystis jirovecii pneumonia (PJP) and other opportunistic respiratory pathogens at Marmara University Pendik Training and Research Hospital.
💡
Conclusion & Impact:In HIV-negative immunosuppressed patients, PJP should be considered, and treatment can be continued if no other factor could be shown and there is high suspicion after taking the required specimen and starting empirical treatment.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:HIV · immünsupresyon · Pneumocystis jirovecii

Abstract

Pneumocystis jirovecii (PJ) is an opportunistic yeast-like fungus that causes pneumonia in immunosuppressed patients. The most risky group is HIV-positive patients, but in recent years it has been more common in HIV-negative immunosuppressed patients. In this study, PJ polymerase chain reaction (PCR) positivity rate, patient risk factors, clinical and laboratory findings were evaluated retrospectively in patients with suspected Pneumocystis jirovecii pneumonia (PJP) and other opportunistic respiratory pathogens at Marmara University Pendik Training and Research Hospital. Pneumocystis jirovecii PCR was studied from the bronchoalveolar lavage sample of a total of 133 patients, and 13 % (17/133) were positive. Forty one % of PCR positive patients were HIV-positive, and 59 % were HIV-negative immunosuppressed patients. Empirical trimethoprim/sulfamethoxazole was initiated in 72 of the patients whose specimens were sent, and treatment was continued in 38 including PCR positive patients. Clinical response was obtained in 9 of 21 PJ PCR negative patients, and no other infectious agents were shown. A total of 66 patients were given steroids because they were hypoxic. Twenty four % of patients who started empirical treatment had positive PJ PCR, and 36 % responded to the treatment. In HIV-negative immunosuppressed patients, PJP should be considered, and treatment can be continued if no other factor could be shown and there is high suspicion after taking the required specimen and starting empirical treatment.

Özet

Pneumocystis jirovecii (PJ) immünosupresif hastalarda pnömoniye sebep olan fırsatçı bir maya benzeri fungustur. En riskli grup HIV-pozitif hastalardır ancak son yıllarda HIV-negatif immünosuprese hastalarda daha sık görülmektedir. Bu çalışmada Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesinde Pneumocystis jirovecii pnömonisi (PJP) ve diğer fırsatçı solunum yolu patojenleri şüphesi ile bronkoskopik örnekleri değerlendirilen hastalarda PJ polimeraz zincir reaksiyonu (PZR) pozitiflik oranı, hasta risk faktörleri, klinik ve laboratuvar bulgularını retrospektif olarak değerlendirilmiştir. Toplam 133 hastanın bronkoalveolar lavaj örneğinden PJ-PZR çalışılmış ve % 13 (17/133) oranında pozitiflik bulunmuştur. PZR pozitif hastaların % 41’inin HIV-pozitif ve % 59’unun HIV-negatif immünosuprese hastalar olduğu görülmüştür. Örnek gönderilen hastaların 72’sine ampirik trimetroprim/sülfametoksazol başlanmış, PZR pozitif hastalarla beraber toplam 38 hastada tedaviye devam edilmiştir. PJ-PZR negatif 21 hastanın dokuzunda klinik yanıt alınmıştır ve başka bir enfeksiyon etkeni gösterilememiştir. Toplam 66 hastaya hipoksik olmaları nedeniyle steroid verilmiştir. Ampirik tedavi baş- lanan hastaların % 24’ünde PJ-PZR pozitifliği ve % 36’sının tedaviye yanıt verdiği görülmüştür. HIV-negatif immün suprese hastalarda PJP akla gelmeli ve gerekli örnek alındıktan ve ampirik tedaviye başlandıktan sonra başka bir etken gösterilemiyorsa ve yüksek klinik şüphe varsa tedaviye devam edilebilir.

🔖

Cite This Article

Sengel, B. E., Alhan, Ö., Sarinoğlu, R. C., Tigen, E. T., Odabaşı, Z. (2020). Pneumocystis jirovecii Positivity and Empirical Treatment Approach in Bronchoalveolar Lavage Samples. ANKEM Dergisi, Cilt: 34 Sayı: 2, 57–64. https://ajindex.com/articles/1190993

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Alshahrani MY, Alfaifi M, Ahmad I, et al. Pneumocystis Jirovecii detection and comparison of multiple diagnostic methods with quantitative real-time PCR in patients with respiratory symptoms. Saudi J Biol Sci. 2020;27(6):1423-7. https://doi.org/10.1016/j.sjbs.2020.04.032
  2. Bollee G, Sarfati C, Thiery G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132(4):1305-10. https://doi.org/10.1378/chest.07-0223
  3. Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virusinfected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29(3):670-2. https://doi.org/10.1086/598651
  4. Ding L, Huang H, Wang H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10(1):34. https://doi.org/10.1186/s13613-020-00649-9
  5. Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015(4):CD006150. https://doi.org/10.1002/14651858.CD006150.pub2
  6. Ide H, Yamaji Y, Tobino K, et al. Pneumocystis jirovecii pneumonia in an immunocompetent Japanese man: a case report and literature review. Case Rep Pulmonol. 2019;2019:3981681. https://doi.org/10.1155/2019/3981681
  7. Jacobs JL, Libby DM, Winters RA, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med. 1991;324(4):246-50. https://doi.org/10.1056/NEJM199101243240407
  8. Kato H, Samukawa S, Takahashi H, et al. Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patientsdifficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole. J Infect Chemother. 2019;25(11):920-4. https://doi.org/10.1016/j.jiac.2019.06.007
  9. Lemiale V, Debrumetz A, Delannoy A, et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14:87. https://doi.org/10.1186/1465-9921-14-87
  10. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204-9. https://doi.org/10.1164/ajrccm/140.5.1204
  11. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96- 128. https://doi.org/10.1164/rccm.2008-740ST
  12. Liu CJ, Lee TF, Ruan SY, et al. Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients. Infect Drug Resist. 2019;12:1457-67. https://doi.org/10.2147/IDR.S199761
  13. Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405-13. https://doi.org/10.1093/jac/dkw158
  14. Matsumura Y, Ito Y, Yamamoto M, et al. Pneumocystis polymerase chain reaction and blood (1-->3)-beta-Dglucan assays to predict survival with suspected Pneumocystis jirovecii pneumonia. J Infect Chemother. 2014;20(2):109-14. https://doi.org/10.1016/j.jiac.2013.09.004
  15. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect Dis. 2015;61(12):1850-61. https://doi.org/10.1093/cid/civ687
  16. Otahbachi M, Nugent K, Buscemi D. Granulomatous Pneumocystis jiroveci pneumonia in a patient with chronic lymphocytic leukemia: a literature review and hypothesis on pathogenesis. Am J Med Sci. 2007;333(2):131-5. https://doi.org/10.1097/00000441-200702000-00014
  17. Salzer HJF, Schafer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIVinfected and non-HIV-infectedi patients with Pneumocystis jirovecii pneumonia. Respiration. 2018;96(1):52-65. https://doi.org/10.1159/000487713
  18. Tasaka S, Tokuda H, Sakai F, et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med. 2010;49(4):273-81. https://doi.org/10.2169/internalmedicine.49.2871
  19. Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1,3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1-2):33-41. https://doi.org/10.1007/s11046-012-9579-y
  20. Thomas CF Jr., Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308. https://doi.org/10.1038/nrmicro1621
  21. White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017;15(5):435-47. https://doi.org/10.1080/14787210.2017.1305887
  22. Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest. 2018;154(3):636-44. https://doi.org/10.1016/j.chest.2018.04.026
  23. Wilson JW, Limper AH, Grys TE, et al. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis. 2011;69(2):145-52. https://doi.org/10.1016/j.diagmicrobio.2010.10.021
  24. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5-13. https://doi.org/10.4065/71.1.5
  25. Zompatori M, Rimondi MR. Diffuse ground-glass opacity of the lung. A guide to interpreting the highresolution computed tomographic (HRCT) picture. Radiol Med. 1994;88(5):576-81.